Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
A dozen states sue the Trump administration to stop tariff policy
A dozen states have sued the Trump administration in the U.S. Court of International Trade to stop its tariff policy, challenging Trump's claim that he could arbitrarily impose tariffs based on the International Emergency Economic Powers Act.
Air pollution still plagues nearly half of Americans. That does a number on our health
Despite improvements in air quality in past decades, 156 million Americans still breathe in too much soot or ozone, says the annual State of the Air report from the American Lung Association.
Eli Lilly sues companies selling alternative versions of its weight loss drug
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of its drug Zepbound.
After a scathing rebuke, judge grants DOJ an extension in deportation case
A federal judge gave the Trump administration another week to answer detailed questions about Kilmar Abrego Garcia, the Maryland man whose illegal deportation has raised concerns about due process.
Funding cut for landmark study of women’s health
The Women's Health Initiative, begun in the 1990s, has made many important discoveries. Now funding to collect more research data will end in September.
After Kashmir attack, India downgrades ties with Pakistan and suspends water treaty
The day after a deadly attack, India announced it was closing a border with Pakistan, downgrading its diplomatic ties and suspending the Indus Waters Treaty. Pakistan denies involvement in the attack.
